#NEWS: Following Phase I results, we're planning to advance a potential new treatment of Geographic Atrophy, one of the leading causes of blindness. We developed the antibody BI 771716 using technology licensed from CDR-Life Inc. Learn more 👉 https://bit.ly/3zadtQv #RetinalDiseases #ClinicalTrials #VisionHealth
Boehringer Ingelheim
Arzneimittelherstellung
Ingelheim am Rhein, Rhineland-Palatinate 1.834.221 Follower:innen
Info
Unsere Mitarbeitenden sind unsere Stärke. Gemeinsam mit über 53.000 Kolleg*innen schaffen wir den nächsten Durchbruch: neue Innovationen für die Gesundheit von Menschen und Tieren.
- Website
-
http://www.boehringer-ingelheim.com
Externer Link zu Boehringer Ingelheim
- Branche
- Arzneimittelherstellung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Ingelheim am Rhein, Rhineland-Palatinate
- Art
- Privatunternehmen
- Spezialgebiete
- Pharmaceuticals, Animal Health, Innovation, Research, Health Care, Improve Health, Biopharmaceuticals und Contract Manufacturing
Orte
Beschäftigte von Boehringer Ingelheim
-
Gwen Whitfield Foster
-
Thomas Macauley
Research Data Management - Lab Services Engineer at Boehringer-Ingelheim
-
Mitchell Taub
Highly Distinguished Research Fellow
-
Ralf Schundelmeier
Product Leader (ex Salesforce) - Building Platforms for Applications, GenAI / Machine Learning & Data
Updates
-
Boehringer Ingelheim hat dies direkt geteilt
We are excited to announce our newly confirmed keynote speaker, H.E. Hanan Mohamed Al Kuwari, minister of public health, Qatar for the upcoming event, ‘MASLD and MASH: prioritising a global public health threat,’ a liver health policy event alongside the UN General Assembly (UNGA) on September 23rd. Supported by Barcelona Institute for Global Health (ISGlobal) programmed by Economist Impact, hear this exclusive keynote session on raising awareness on MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis) and how government leaders can prioritise awareness and action. Register today: https://lnkd.in/gqFqSQPs The event is supported financially by Novo Nordisk, Boehringer Ingelheim, Echosens, CUNY Graduate School of Public Health and Health Policy and the CUNY SPH Foundation. #MASLD #MASH #UNGA
-
-
#NEWS: We have acquired Saiba Animal Health AG. We are very excited to add their novel development program to our animal health R&D pipeline in the fast-growing pet therapeutics market segment. Learn more about the unique approach using virus-like particles to stimulate the immune system, and how it may lead to new treatments for pets suffering from chronic diseases such as allergy, inflammation or pain: https://lnkd.in/eJgD3uh3 #PetTherapeutics
-
-
Are you active in the fight against rabies, or do you know somebody who is? Then apply for the #WorldRabiesDay Award or nominate a colleague or a friend. Nominations are now open for these categories: 🩺 Veterinary clinic champion 💡 Education champion 💉 Vaccination champion 🐾 Animal welfare champion Winners get additional funding for their not-for-profit work, enabling them to make an even greater difference for communities that are threatened by rabies. Apply here: https://lnkd.in/eJwBb_Vf
-
-
#NEWS: New responsibilities in Boehringer Ingelheim´s Board of Managing Directors (BMD) as of October 1, 2024. ➡️ Carinne Brouillon, member of the BMD with responsibility for the Human Pharma Business Unit will retire. ➡️ Shashank Deshpande, who currently leads the Animal Health Business, will succeed Carinne in her role. ➡️ For the Animal Health Business Unit, Dr. Armin Wiesler, will be appointed as a member of the BMD. Learn more: https://lnkd.in/gU5PUGps #LifeForward
-
-
Did you know one in five people are at risk of developing heart failure in their lifetime? Our colleague Sandy Sommer Head of the Therapeutic Area Cardiovascular, Renal, & Metabolic, recently discussed our commitment to finding new solutions for people living with heart failure and connected conditions of the cardiovascular, renal and metabolic system. Learn more here: https://bit.ly/4dMuY8v #LifeForward #HeartFailure #HeartHealth
-
-
When it comes to #ChronicKidneyDisease (CKD), 2 tests lead to better outcomes. Nearly 80% of people with CKD only receive one test. For complete testing, two tests are vital to getting a full diagnosis – UACR (urine) and eGFR (blood). Learn more here: https://lnkd.in/eeGunneV
-
#NEWS: Transformative results will be shared at the 2024 World Conference on Lung Cancer. Breakthrough Therapy Designation by both the U.S. FDA and China's CDE, has been granted to our investigational medicine for patients with HER2-mutated non-small cell lung cancer and who have received prior systemic therapy. Our dedication to innovation continues to drive our extensive oncology pipeline, aiming to address the critical needs of patients globally. Learn more: https://lnkd.in/eHRkpueb #LungCancer #OncologyResearch #WCLC24
-
-
Did you know that dogs’ needs change significantly as they age? This #InternationalDogDay is about knowing how to keep your furry friend healthy at every stage of life. Learn more about the unique needs of puppies, adult dogs and senior dogs: https://lnkd.in/etFZ8r8T
-
#HCP: Tango is a dance in which 2 people communicate through their movements. In the same way, it also takes 2 tests to get the full picture about #ChronicKidneyDisease (CKD). Follow clinical guidelines from diabetes and kidney organizations and issue 2 tests – an eGFR (blood) and UACR (urine) tests. Learn more here: https://lnkd.in/ezK2JNTY
-